Sanofi reinforces collaboration with Stevenage Bioscience Catalyst with partnering office
pharmafile | April 13, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Sanofi, Stevenage Bioscience Catalyst, academia, industry, partnership, pharma, stevenage
Sanofi has reinforced its collaboration with Stevenage Bioscience Catalyst with the opening of a new partnering office. This office will foster engagement and collaboration between the French pharma company and the network of bioscience companies and academia that form a part of the UK’s vibrant life sciences ecosystem.
Stevenage Bioscience Catalyst was opened as the UK’s first open innovation biomedical campus in 2012 and combines infrastructure and virtual networks to drive collaboration. With the first phase of their plan completed, its second stage will focus on open innovation and convergent medical technologies.
These aims dovetail well with Sanofi’s plan to work with global partners to develop high quality scientific research in areas of unmet need, such as diabetes, oncology, multiple sclerosis and infectious diseases.
Yvonne Naughton, head of external science and partnering at Sanofi UK & Ireland, says: “At Sanofi we recognise that the next big discovery may come from outside of our own laboratories. Core to our strategy is to build strong relationships with biotechnology organisations, research institutes and academic centres.”
Martino Picardo, CEO of Stevenage Bioscience Catalyst, comments: “Sanofi is a fantastic addition to the thriving ecosystem developing here, and we are delighted that it recognises the value of being part of our innovation-focused community. With Sanofi’s focus on transformative new medicines and openness to external innovation, there is a strong strategic fit with SBC and we anticipate a long and fruitful relationship.”
Sean Murray
Related Content
Landmark Bio and Mass General Brigham partner to accelerate translational CGT therapies
Landmark Bio and Mass General Brigham in the US have entered a new strategic collaboration …
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
